A Phase II Study of Tivozanib in Recurrent Glioblastoma

Trial Profile

A Phase II Study of Tivozanib in Recurrent Glioblastoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Tivozanib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015 as per ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2015 Primary endpoint has not been met (determine proportion of patients alive and progression free after 6) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top